PharmacoEconomics

, Volume 8, Issue 3, pp 199–222 | Cite as

Measuring the Costs of Schizophrenia

Implications for the Post-Institutional Era in the US
  • Kenneth C. Terkelsen
  • Alan Menikoff
Review Article

Summary

Schizophrenia is a stress-related biomedical condition of the brain. characterised by unusual internal experiences. severe and often persistent functional disability and socially inappropriate behaviour. It is estimated that schizophrenia affects approltimateiy 1 % of all adults worldwide. Young adults are especially vulnerable. It is an illness with profound economic impact on patients. their families and society at large.

Before the 1950s, most patients with schizophrenia were admitted to hospital for long inpatient stays. Keeping the patient in an institutional setting was all that psychiatry could offer, because there was little active treatment available. After World War II, and especially fol lowing the introduction of chlorpromazine in 1954, treatment was offered increasingly in outpatient settings. At present, more than 90% of individuals with schizophrenia will receive most healthcare services in outpatient facilities, supplemented by brief hospital treatment.

The trend toward community-based care continues into the 1990s, supported in part by recent pharmacotherapeutic developments that are making a new generation of drug treatment options available. Clozapine, the mosl widely used of these new drugs, has been the subject of several studies that compared its costs with those of conventional drug treatments. These early studies suggest that further reductions in the cost of hospital treatment are possible in the near future.

At the same time, despite the increasing availability of effective treatment in outpatient settings, the shift of resources from institutional to community care will not occur as quickly as some might wish. Delays in the transformation of care systems are caused by political interest groups and the sheer inertia of the infrastructure left over from the era of institutional care. These factors must be taken into account in estimating the cost of schizophrenia care during the next decade.

The aim of this review is to provide a clinical picture of schizophrenia, emphasising features that contribute most to the cost of illness. We define and quantify the direct and indirect costs of the illness, discuss the cost implications of new pharmacotherapeutic and psychosocial treatments, and critique strategies for measuring the economic efficacy of these new treatments. The difficulties in measuring the costs of schizophrenia that are related to the transition from institutional to community-based systems of care in the US are also reviewed.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hyde TM, Weinberger DR. The brain in schizophrenia. Semin Neurol 1990; 10 (3): 276–86CrossRefGoogle Scholar
  2. 2.
    Kendler KS, Diehi SR. The genetics of schizophrenia; a current, genetic-epidemiologic perspective. Schizophr Bull 1993; 19(2): 261–85PubMedCrossRefGoogle Scholar
  3. 3.
    Brixley SN, Gallagher BJ, McFalls JA, et al. Gestational and neonatal factors in the etiology of schizophrenia. J Clin Psychol 1993; 49(3): 447–56CrossRefGoogle Scholar
  4. 4.
    Pilowsky LS, Kerwin RW, Murray RM. Schizophrenia: a neurodevelopmental perspective. Neuropsychopharmacology 1993; 9 (1): 83–91Google Scholar
  5. 5.
    Pert CB, Knight JG, Laing P, et al. Scenarios for a viral etiology of schizophrenia. Schizophr Bull 1988; 14(2): 243–7PubMedCrossRefGoogle Scholar
  6. 6.
    Freedman R, Waldo M, Bickford-Wimer P, et al. Elementary neuronal dysfunction in schizophrenia. Schizophr Res 1991; 4(2): 233–43PubMedCrossRefGoogle Scholar
  7. 7.
    Judd LL, McAdams L, Budnick B. et al. Sensory gating deficits in schizophrenia; new results. Am J Psychiatry 1992; 149(4): 488–93PubMedGoogle Scholar
  8. 8.
    Adler LE, Waldo MC, Tatcher A, et al. Lack of relationship of auditory gating defects to negative symptoms in schizophrenia. Schizophr Res 1990; 3(2): 131–8PubMedCrossRefGoogle Scholar
  9. 9.
    Crow TJ. Molecular pathology of schizophrenia: more than one disease process? BMJ 1980; 280: 66–8PubMedCrossRefGoogle Scholar
  10. 10.
    Andreasen NC. The broken brain. New York: Harper & Row, 1984Google Scholar
  11. 11.
    Toney EF. A viral-anatomical explanation of schizophrenia. Schizophr Bull 1991; 17(I): 15–8Google Scholar
  12. 12.
    Adler LE, Waldo MC. Counterpoint; a sensory gating-hippocampal model of schizophrenia. Schizophr Bull 1991; 17(1): 19–24PubMedCrossRefGoogle Scholar
  13. 13.
    Sarlorius N, Jablensky A, Korten A, et al. Early manifestations and first-contact incidence of schizophrenia in different cultures: a preliminary report on the evaluation of the WHO Collaborative Study in Determinants of Outcome of Severe Mental Disorders. Psychol Med 1986; 16: 909–28CrossRefGoogle Scholar
  14. 14.
    Robins LN, Heizer JE, Weissman MM. et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41: 949–58PubMedCrossRefGoogle Scholar
  15. 15.
    Leff JP. Schizophrenia and sensitivity to the environment. Schizophr Bull 1976; 2: 566–74PubMedCrossRefGoogle Scholar
  16. 16.
    North CS. Current concepts of schizophrenia. Compr Ther 1989; 15(3): 8–21PubMedGoogle Scholar
  17. 17.
    Andreasen NC, Flaum M. Schizophrenia: the characteristic symptoms. Schizophr Bull 1991; 17(1): 27–49PubMedCrossRefGoogle Scholar
  18. 18.
    Amador X, Strauss DH, Yale SA, et al. Awareness of illness in schizophrenia. Schizophr Bull 1991; 17(1): 113–32PubMedCrossRefGoogle Scholar
  19. 19.
    McGlashan TH, Fenton WS. The positive-negative distinction in schizophrenia: review of natural history validators. Arch Gen Psychiatry 1992; 49(1): 63–72PubMedCrossRefGoogle Scholar
  20. 20.
    Tabbane K, Joober R, Spadone C. et al. Mortality and cause of death in schizophrenia: review of the literature. Encephale 1993; 19(1): 23–8PubMedGoogle Scholar
  21. 21.
    Glassman AH. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 1993; 150(4): 546–53PubMedGoogle Scholar
  22. 22.
    Ziedonis DM, Kosten TR, Glazer WM, et al. Nicotine dependence and schizophrenia. Hosp Community Psychiatry 1994; 45(3): 204–6PubMedGoogle Scholar
  23. 23.
    Martinez JA, Velasco JJ, Urbistondo MD. Effects of pharmacological therapy on anthropometric and biochemical status of male and femaie institutionalized psychiatric patients. J Am Coll Nutr 1994; 13(2): 192–7PubMedGoogle Scholar
  24. 24.
    Mortensen PB, Juel K. Mortality and causes of death in schizophrenic patients in Denmark. Acta Psychiatr Scand 1990; 81(4): 372–7PubMedCrossRefGoogle Scholar
  25. 25.
    Masterson E, O’Shea B. Smoking and malignancy in schizophrenia. Br J Psychiatry 1984; 145: 429–32PubMedCrossRefGoogle Scholar
  26. 26.
    Koran LM, Sox HC, Marton KI, et al. Medical evaluation of psychiatric patients. Arch Gen Psychiatry 1989; 46(8): 733–40PubMedCrossRefGoogle Scholar
  27. 27.
    Minkoff K, Drake RE. Dual diagnosis of major mental illness and substance disorder. San Francisco: Jossey-Bass, 1991Google Scholar
  28. 28.
    Cournos F, Empfield M, Horwalh E, et al. HIV seroprevalence among patients admitted to two psychiatric hospitals. Am J Psychiatry 1991; 148: 1225–30PubMedGoogle Scholar
  29. 29.
    Sacks M, Dermatis H, Burton W, et al. Acute psychiatric illness: effects on HIV-risk behavior. Psychosoc Rehabil J 1994; 17: 5–18Google Scholar
  30. 30.
    Regier DA, Burke JD, Manderschcid RW, et al. The chronically mentally ill in primary care. Psychol Med 1985; 15: 265–73PubMedCrossRefGoogle Scholar
  31. 31.
    Wing JK. A simple and reliable subelassification of chronic schizophrenia. J Ment Sci 1961; 107: 862–75PubMedGoogle Scholar
  32. 32.
    Liddle PF. The symptoms of chronic schizophrenia: are-examination of the positive-negative dichotomy. Br J Psychiatry 1987; 151: 145–51PubMedCrossRefGoogle Scholar
  33. 33.
    Blackwell B. Drug therapy: patient compliance. N Engl J Med 1973; 289: 249–52PubMedCrossRefGoogle Scholar
  34. 34.
    Blackwell B. Treatment adherence. Br J Psychiatry 1976; 129: 513–31PubMedCrossRefGoogle Scholar
  35. 35.
    Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31: 67–72PubMedCrossRefGoogle Scholar
  36. 36.
    Bartkó G, Kerczeg I, Zádor G. Clinical symptomatology and drug compliance in schizophrenic patients. Acta Psychiatr Scand 1988; 77: 74–6PubMedCrossRefGoogle Scholar
  37. 37.
    Günther V, Meise U. Compliance: ein komplexes problem. Wien Med Wochenschr 1990; 140: 365–9PubMedGoogle Scholar
  38. 38.
    Van Putten T, Marder SR, Wirshing WC, et al. Surreptitious noncompliance with oral fluphenazine in a voluntary inpatient population [letter]. Arch Gen Psychiatry 1990; 47(8): 786–7PubMedCrossRefGoogle Scholar
  39. 39.
    Green JH. Frequent rehospitalization and noncompliance with treatment. Hosp Community Psychiatry 1988; 39(9): 963–6PubMedGoogle Scholar
  40. 40.
    Teplin LA. The prevalence of severe mental disorder among male urban jail detainees: comparison with Epidemiological Catchment Area Program. Am J Public Health 1990; 80: 639–69CrossRefGoogle Scholar
  41. 41.
    Opler LA, Caton CLM, Shrout P, et al. Symptom profiles and homelessness in schizophrenia. J Nerv Ment Dis 1994; 182: 174–8PubMedCrossRefGoogle Scholar
  42. 42.
    Weiden PJ. The cost of relapse: the noncompliance factor. 147th American Psychiatric Association Annuai Meeting; 1994 May 24: Philadelphia (PA). 311Google Scholar
  43. 43.
    Susser E, Streuning EL, Conover S. Psychiatric problems in homeless men: lifetime psychosis, substance use, and current distress in new arrivals at New York City shelters. Arch Gen Psychiatry 1989; 46: 845–50PubMedCrossRefGoogle Scholar
  44. 44.
    Geddes J, Newton R, Young G, et al. Comparison of prevalence of schizophrenia among residents of hostels for homeless people in 1966 and 1992. BMJ 1994; 308: 816–9PubMedCrossRefGoogle Scholar
  45. 45.
    Drake RE, Wallach MA, Teague GB, et al. Housing instability and homelessness among rural schizophrenic patients. Am J Psychiatry 1991; 148: 330–6PubMedGoogle Scholar
  46. 46.
    Virgona A, Buhrich N, Teeson M. Prevalence of schizophrenia among women in refuges for the homeless. Aust N Z J Psychiatry 1993; 27: 405–10PubMedCrossRefGoogle Scholar
  47. 47.
    Grinspoon L, Ewalt JR, Shader RL editors. Schizophrenia: pharmacotherapy and psychotherapy. Baltimore: Williams & Wilkins, 1972Google Scholar
  48. 48.
    Hogarty GE, Goldberg SC. the Collaborative Study Group. Drug and sociotherapy in the aftercare of schizophrenic patients: one year relapse rates. Arch Gen Psychiatry 1973; 28: 54–64PubMedCrossRefGoogle Scholar
  49. 49.
    Bachrach L. Principles of planning for chronic psychiatric patients: a synthesis. In; Talbotl JA, editor. The chronic mental patient; five years later. Orlando (FL): Grime & Stratton, 1984: 165–82Google Scholar
  50. 50.
    Wyatl RJ. Antipsychotics and the natural course of schizophrenia. Schizophr Bull 1991; 17: 325–51CrossRefGoogle Scholar
  51. 51.
    Delay J, Deniker P, Harl JM. Utilization en thérapeutique psychiatrique d’une phenothiazine d’action cenlrale elective (4560 RP). Ann Med Psychol 1952; 110: 112–7Google Scholar
  52. 52.
    Lehmann HE, Hanrahan GE. Chlorpromazine, a new inhibiting agent for psychomotor excitement and manic states. AMA Arch Neurol Psychiatry 1954; 71: 227–37PubMedCrossRefGoogle Scholar
  53. 53.
    Casey JF, Bennett IR, Lindley CJ, et al. Drug therapy in schizophrenia. Arch Gen Psychiatry 1960; 2: 210–20CrossRefGoogle Scholar
  54. 54.
    National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964; 10: 246-61Google Scholar
  55. 55.
    Kline NS, Stanley AM. Use of reserpine in a neuropsychiatric hospital. Ann N Y Acad Sci 1955; 61: 85–91PubMedCrossRefGoogle Scholar
  56. 56.
    Finn MHP, Nadolski F, Guy W, et al. Clinical, psychological, and myoneural changes in psychotic patients under oral Serpasil medication. J Nerv Ment Dis 1955; 122: 458–62PubMedCrossRefGoogle Scholar
  57. 57.
    Cheung HK, Schizophrenics fully remitted on antipsychotics for 3-5 years: to slop or continue drugs? Br J Psychiatry 1981; 138: 490–4PubMedCrossRefGoogle Scholar
  58. 58.
    Wistedt B, Jorgensen A, Wiles D. A depot antipsychotic withdrawal study. Psychopharmacology 1982; 78: 301–4PubMedCrossRefGoogle Scholar
  59. 59.
    Johnson DAW, Pasterski C, Ludlow JM, et al. The discontinuance of maintenance antipsychotic therapy in chronic schisophrenic patients: drug and social consequences. Acta Psychiatr Scand 1983; 67: 339–52PubMedCrossRefGoogle Scholar
  60. 60.
    Gilbert PL, Harris J, McAdams LA, et al. Antipsychotic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995; 52(3): 173–88PubMedCrossRefGoogle Scholar
  61. 61.
    Siris SG. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. Br J Psychiatry Suppl 1993; 22: 66–78PubMedGoogle Scholar
  62. 62.
    Schooler NR. Reducing dosage in maintenance treatment of schizophrenia: review and prognosis. Br J Psychiatry Suppl 1993; 22: 58–65PubMedGoogle Scholar
  63. 63.
    Kane JM. Dosage strategies with long-acting injectable antipsychotics, including haloperidol decanoate. J Clin Psychopharmacol 1986; 6(1 Suppl,): 20–3Google Scholar
  64. 64.
    Marder SR. Depot antipsychotics: side effects and safety. J Clin Psychopharmacol 1986; 6(1 Suppl.): 24–9Google Scholar
  65. 65.
    Christison GW, Kirsch DF, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991; 17(1): 217–45PubMedCrossRefGoogle Scholar
  66. 66.
    Brambilla F, Scarone J, Ponzano M, et al. Catecholamine drugs in chronic schizophrenia. Neuropsychobiology 1979; 5: 185–200PubMedCrossRefGoogle Scholar
  67. 67.
    Plasky P. Antidepressant usage in schizophrenia. Schizophr Bull 1991; 17(4): 649–57PubMedCrossRefGoogle Scholar
  68. 68.
    Amsler HA, Teerenhovi L, Barth E, et al. Agranulocytosis in patients treated with clozapine: a study of the Finnish epidemic. Acta Psychiatr Scand 1977; 56(4): 241–8PubMedCrossRefGoogle Scholar
  69. 69.
    Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45: 789–96PubMedCrossRefGoogle Scholar
  70. 70.
    Alvir JMJ, Liebcrman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162–7PubMedCrossRefGoogle Scholar
  71. 71.
    Land W, Salzman C. Risperidone: a novel antipsychotic medication. Hosp Community Psychiatry 1994; 45: 434–5PubMedGoogle Scholar
  72. 72.
    Moore NA, Tye NC, Axton MS, et al. The behavioral pharmacology of olanzapine, a novel ‘atypical’ antipsychotic agent. J Pharmacol Exp Ther 1992; 262(2): 545–51PubMedGoogle Scholar
  73. 73.
    Hyttel J, Arnt J, Costall B, et al. Pharmacological profile of the atypical antipsychotic sertindole. Clin Neuropharmacol 1992; 15Suppl. 1, Pt A: 267–8CrossRefGoogle Scholar
  74. 74.
    Meltzer HY. Novel antipsychotic drugs. New York: Raven Press, 1992Google Scholar
  75. 75.
    Rothman D. Discovery of the asylum: social order and disorder in the new republic. Boston: Liltle Brown & Co., 1971Google Scholar
  76. 76.
    Cutting J. Outcome of schizophrenia: overview. In: Kerr TA, Shaith P. editors. Contemporary issues in schizophrenia. Washington, DC: American Psychiatric Press, 1986: 433–40Google Scholar
  77. 77.
    New York State Office of Mental Health (NYSOMH) Mental Health Statistics Unit. Statewide chartbook of mental health information. Albany: NYSOMH. 1994Google Scholar
  78. 78.
    Wilson GF, Phillips KL. Utilization review criteria for adult extended hospitalization. In: Maltson MR, editor. Manual of psychiatric quality assurance. Washington. DC: American Psychiatric Association, 1992: 121–6Google Scholar
  79. 79.
    Gabbard GO. Comparative indications for brief and extended hospitalization. In: Tasman A, Riba MB, editors. Review of psychiatry. Vol II. Washington. DC: American Psychiatric Press, 1992: 503–17Google Scholar
  80. 80.
    Love RE, The community support program: strategy for reform? In: Talbott JA. editor. The chronic mental patient: five years later. Orlando (FL): Grune & Stratton, 1984: 195–214Google Scholar
  81. 81.
    Turner JC, TenHoor WJ. The NIMH Community Support Program: pilot approach to a needed social reform. Schizophr Bull 1978; 4: 319–48CrossRefGoogle Scholar
  82. 82.
    Foumier JP, Gagnon F. A crisis intervention service in an out-patient psychiatric clinic of a general hospital: function and clientele. Am J Psychiatry 1993; 38: 96–100Google Scholar
  83. 83.
    Pigott HE, Trott L. Translating research into practice: the implementation of an in-home crisis intervention triage and treatment service in the private sector. Am J Med Qual 1993; 8: 138–44PubMedCrossRefGoogle Scholar
  84. 84.
    Pasaminick B, Scarpitti F, Dinitz S. Schizophrenics in the community: an experimental sludy in the prevention of hospitalization. New York: Appleton-Century-Crofts, 1967Google Scholar
  85. 85.
    Langsley DG, Kaplan DM. The treatment of families in crisis. New York: Grune & Stratton, 1968Google Scholar
  86. 86.
    Bengelsdorf H, Church JO, Kaye RA, et al. The cost effectiveness of crisis intervention: admission diversion savings can offset the high cost of service. J Nerv Ment Dis 1993; 181(12): 757–62PubMedCrossRefGoogle Scholar
  87. 87.
    Stein LI. A system approach to reducing relapse in schizophrenia. J Clin Psychiatry 1993; 54Suppl.: 7–12PubMedGoogle Scholar
  88. 88.
    Stein LI, Test MA. Alternatives to menial hospital treatment. New York: Plenum, 1978Google Scholar
  89. 89.
    Stein LI, Test MA. Alternative to mental hospital treatment: I. Conceptual model, treatment program, and clinical evaluation. Arch Gen Psychiatry 1980; 37(4): 392–7PubMedCrossRefGoogle Scholar
  90. 90.
    Weisbrod BA, Test MA, Stein LI. Alternative to mental hospital treatment: 11. Economic benefil-cost analysis. Arch Gen Psychiatry 1980; 37(4): 400–5PubMedCrossRefGoogle Scholar
  91. 91.
    Hornstra RK, Bruce-Wolfe V, Sagduyu K, et al. The effect of intensive case management on hospitalization of patients with schizophrenia. Hosp Community Psychiatry 1993; 44(9): 844–7PubMedGoogle Scholar
  92. 92.
    Dixon L, Friedman N, Lehman A. Compliance of homeless mentally ill persons with assertive community treatment. Hosp Community Psychiatry 1993; 44(6): 581–3PubMedGoogle Scholar
  93. 93.
    Santos AB, Deci PA, Lachance KR, et al. Providing assertive community treatment for severely mentally ill patients in a rural area. Hosp Community Psychiatry 1993; 44(I): 34–9PubMedGoogle Scholar
  94. 94.
    Dincin J, Wasmer D, Witheridgc TF, et al. Impact of assertive community treatment on the use of stale hospital inpatient bed-days. Hosp Community Psychiatry 1993; 44(9): 833–8PubMedGoogle Scholar
  95. 95.
    Olfson M. Assertive community treatment: an evaluation of the experimental evidence. Hosp Community Psychiatry 1990; 41: 634–41PubMedGoogle Scholar
  96. 96.
    Brown GW, Birley JLT, Wing JK. Influence of family life on the course of schizophrenic disorders: a replication. Br J Psychiatry 1972; 121: 241–58PubMedCrossRefGoogle Scholar
  97. 97.
    Vaughn CE, Leff JP. The influence of family and social factors on the course of psychiatric illness: a comparison of schizophrenic and depressed neurotic patients. Br J Psychiatry 1976; 129: 125–37PubMedCrossRefGoogle Scholar
  98. 98.
    Lehtinen K. Need-adapted treatment of schizophrenia: a five-year follow-up study from the Turku project. Acta Psychiatr Scand 1993; 87(2): 96–101PubMedCrossRefGoogle Scholar
  99. 99.
    Gottschalk LA, Kentingc C. Influence of patient caregivers on course of patient illness: ‘expressed emotion’ and alternative measures. J Clin Psychol 1993; 49(6): 898–912PubMedCrossRefGoogle Scholar
  100. 100.
    Liberman RP, editor. Psychiatric rehabilitation of chronic mental patients. Washington. DC: American Psychiatric Press. 1988Google Scholar
  101. 101.
    Anthony W, Cohen M, Farkas M. Psychiatric rehabilitation. Boston: Center for Psychiatric Rehabilitation, 1990Google Scholar
  102. 102.
    Liberman RP, editor. Handbook of psychiatric rehabilitation. Boston: Allyn and Bacon, 1993Google Scholar
  103. 103.
    Dzhagarov M. Experience in organizing a half hospital for mental patients. Neuropathol Psikhatria 1937; 6: 137–47Google Scholar
  104. 104.
    Cameron DE. The day hospital: experimental forms of hospitalization for patients. Mod Hosp 1947; 69(3): 60–2PubMedGoogle Scholar
  105. 105.
    Bierer J. Therapeutic social clubs. London: HK Lewis, 1948Google Scholar
  106. 106.
    Herz MI, Endicott J, Spitzer RL, et al. Day versus inpatient hospitalization: a controlled study. Am J Psychiatry 1971; 127(10): 1371–82PubMedGoogle Scholar
  107. 107.
    Guilette W, Crowley B, Savitz SA, et al. Day hospitalization as a cost-effective alternative to inpatient care: a pilot study. Hosp Community Psychiatry 1978; 29(8): 525–7Google Scholar
  108. 108.
    Wiersma D, Kluiter H, Nienhuls FJ, et al. Costs and benefits of day treatment with community care for schizophrenic patients. Schizophr Bull 1991; 17(3): 411–9PubMedCrossRefGoogle Scholar
  109. 109.
    Gudeman JE, Dickey B, Evans A, et al. Four-year assessment of a day hospital-inn program as an alternative to inpatient hospitalization. Am J Psychiatry 1985; 142(11): 1330–3PubMedGoogle Scholar
  110. 110.
    Linn MW, Caffey EM, Kielt J, et al. Day treatment and psychotropic drugs in the aftercare of schizophrenic patients: a Veterans Administration cooperative study. Arch Gen Psychiatry 1979; 36: 1055–66PubMedCrossRefGoogle Scholar
  111. 111.
    Muiler P. Psychotherapy in schizophrenic psychoses - historical development, effectiveness and currently accepted methods. Fonschr Neurol Psychiatr 1991; 59(7): 277–85CrossRefGoogle Scholar
  112. 112.
    Gunderson JG, Frank AF, Katz HM, et al. Effects of psychotherapy in schizophrenia: II. Comparative outcome of two forms of treatment. Schizophr Bull 1984; 10(4): 564–98PubMedCrossRefGoogle Scholar
  113. 113.
    Kates J, Rockland LH. Supportive psychotherapy of the schizophrenic patient. Am J Psychother 1994; 48(4): 543–61PubMedGoogle Scholar
  114. 114.
    Kahn EM, Kahn EW. Group treatment assignment for outpatients with schizophrenia: integrating recent clinical and research findings. Community Ment Health J 1992; 28(6): 539–50PubMedCrossRefGoogle Scholar
  115. 115.
    Falloon IR. Psychotherapy of schizophrenia. Br J Hosp Med 1992; 48(3-4): 164–70PubMedGoogle Scholar
  116. 116.
    Kuchenhoff B, Hell D. Treatment of schizophrenia in clinical practice. Schweiz Rundseh Med Prax 1993; 82(17): 510–5Google Scholar
  117. 117.
    Strauss JS. Intensive clinical studies: the psychotherapy of schizophrenia. Psychiatry 1993; 56(3): 282–3PubMedGoogle Scholar
  118. 118.
    May PRA. Treatment of schizophrenia: a comparative study of five treatment methods. New York: Science House, 1968Google Scholar
  119. 119.
    Mosher LR, Keith SJ. Psychosocial treatment: individual, group, family and community support approaches. Schizophr Bull 1980; 6: 10–41PubMedCrossRefGoogle Scholar
  120. 120.
    Kraepelin E. Dementia praecox and paraphrenia (1919). Translated by RM Barclay. New York: Robert E Kreiger Publishing Company, 1971Google Scholar
  121. 121.
    Bleuler M. The long-term course of the schizophrenic psychoses. Psychol Med 1974; 4: 244–54CrossRefGoogle Scholar
  122. 122.
    Bleuler M. The schizophrenic disorders: long-term patient and family studies. New Haven (CT): Yale University Press, 1978Google Scholar
  123. 123.
    Ciompi L. The natural history of schizophrenia in the long term. Br J Psychiatry 1980; 136: 413–20PubMedCrossRefGoogle Scholar
  124. 124.
    Harding CM, Brooks GW, Ashikaga T, et al. The Vermont longitudinal study of persons with severe mental illness: II. Long-term outcome of subjects who retrospectively met DSM-lil criteria for schizophrenia. Am J Psychiatry 1987; 144(6): 727–35PubMedGoogle Scholar
  125. 125.
    Cohen P, Cohen J. The clinician’s illusion. Arch Gen Psychiatry 1984; 41: 1178–82PubMedCrossRefGoogle Scholar
  126. 126.
    Harding CM, Zubin J, Strauss JS. Chronicity in schizophrenia: fact, partial fact or artifact? Hosp Community Psychiatry 1987; 38: 477–86PubMedGoogle Scholar
  127. 127.
    Eaton WW, Bilker W, Haro JM. et al. Long-term course of hospitalization for schizophrenia: II. Change with passage of time. Schizophr Bull 1992; 18(2): 229–41PubMedCrossRefGoogle Scholar
  128. 128.
    Breier A, Strauss JS. Self-control in psychotic disorders. Arch Gen Psychiatry 1983; 40(10): 1141–5PubMedCrossRefGoogle Scholar
  129. 129.
    Davidson L, Strauss JS. Sense of self in recovery from severe mental illness. Br J Med Psychol 1992; 65(Pt 2): 131–45PubMedCrossRefGoogle Scholar
  130. 130.
    Sehlaff C. From dependency to self-advocacy: redefining disability. Am J Occup Ther 1993; 47(10): 943–8CrossRefGoogle Scholar
  131. 131.
    Werry JS, McClellan JM. Predicting outcome in child and adolescent (early onset) schizophrenia and bipolar disorder. J Am Acad Child Adolesc Psychiatry 1992; 31(1): 147–50PubMedCrossRefGoogle Scholar
  132. 132.
    Carpenter Jr WT, Kirkpatrick B. The heterogeneity of the long-term course of schizophrenia. Schizophr Bull 1988; 14: 645–52PubMedCrossRefGoogle Scholar
  133. 133.
    Lamb RH. What did we really expect from deinstitutionalization? Hosp Community Psychiatry 1981; 32: 105–9PubMedGoogle Scholar
  134. 134.
    Anthony WA, Cohen MR, Vitalo R. The measurement of rehabilitative outcome. Schizophr Bull 1978; 4: 365–83CrossRefGoogle Scholar
  135. 135.
    Hera MI. Recognizing and preventing relapse in patients with schizophrenia. Hosp Community Psychiatry 1984; 35: 344–9Google Scholar
  136. 136.
    Andreasen NC. Assessment issues and the cost of schizophrenia. Schizophr Bull 1991; 17(3): 475–81PubMedCrossRefGoogle Scholar
  137. 137.
    Sharfstein SS. Prospective cost allocations for the chronic schizophrenic patient. Schizophr Bull 1991; 17(3): 395–400CrossRefGoogle Scholar
  138. 138.
    Rice DP, Kelman S, Miller LS, et al. The economic costs of alcohol and drug abuse and mental illness: 1985. San Francisco; Institute for Health and Aging, University of California, 1990Google Scholar
  139. 139.
    Anient A, Evers S. Cost of illness studies in health care: a comparison of two cases. Health Policy 1993; 26: 29–42CrossRefGoogle Scholar
  140. 140.
    Cassel EJ. The nature of suffering and the goals of medicine. N Engl J Med 1982; 306: 639–45PubMedCrossRefGoogle Scholar
  141. 141.
    Scheffler RM, Foreman SE, Cuffel BJ, et al. Mental health benefits in the Clinton plan. Health Aff 1994; 13: 201–10CrossRefGoogle Scholar
  142. 142.
    Terkelsen KG, Grosser RC, Estimating clozapine’s cost to the nation. Hosp Community Psychiatry 1990; 41(8): 863–9PubMedGoogle Scholar
  143. 143.
    Weisbrod BA. A guide to benefit-cost analysis as seen through a controlled Experiment in treating the mentally ill. J Health Polit Policy Law 1983; 7: 808–45PubMedCrossRefGoogle Scholar
  144. 144.
    Hing E, Sekscenski E, Strahan G. The national nursing home survey: 1985 summary for the United Stales. Publication No. (PHS) 89-1758 (Vital Health Statistics; vol. 13, no. 97) Washington, DC: US Government Printing Office, Department of Health and Human Services, 1989Google Scholar
  145. 145.
    National prescription audit. Ambler (PA): IMS America, 1985Google Scholar
  146. 146.
    Zorc JJ, Larson DB, Lyons JS, et al. Expenditures for psychotropic medications in the United States in 1985. Am J Psychiatry 1991; 148: 644–7PubMedGoogle Scholar
  147. 147.
    Allebeck P. Schizophrenia; a life-shortening disease. Schizophr Bull 1989; 15: 81–9PubMedCrossRefGoogle Scholar
  148. 148.
    Berren MR, Hill KR, Merikle E, et al. Serious mental illness and mortality rates. Hosp Community Psychiatry 1994; 45: 604–5PubMedGoogle Scholar
  149. 149.
    Goldman HH. Mental illness and family burden: a public health perspective. Hosp Community Psychiatry 1982; 33: 557–60PubMedGoogle Scholar
  150. 150.
    Franks DD, The high cost of caring: economic contributions of families to the care of the mentally ill [dissertation). Waltham (MA): Brandeis University, 1987Google Scholar
  151. 151.
    McGuire TG. Measuring the economic costs of schizophrenia. Schizophr Bull 1991; 17: 375–88PubMedCrossRefGoogle Scholar
  152. 152.
    Clark RE. Family costs associated with severe mental illness and substance abuse. Hosp Community Psychiatry 1994; 45(8): 808–13PubMedGoogle Scholar
  153. 153.
    Goldman HH. Epidemiology In: Talbott JA, editor. The chronic mental patient: live years later. Orlando (FL): Grune & Stratton, 1984: 15–31Google Scholar
  154. 154.
    Salleh MR, The burden of care of schizophrenia in Malay families. Acta Psychiatr Scand 1994; 89(3): 180–5PubMedCrossRefGoogle Scholar
  155. 155.
    Lehman AF, Linn LS. Crimes against discharged mental patients in board-and-care homes. Am J Psychiatry 1984; 141(2): 271–4PubMedGoogle Scholar
  156. 156.
    Brown P. The transfer of care: psychiatric deinstitutionalization and its aftermath. London: Routledge & Kegen Paul, 1985Google Scholar
  157. 157.
    Swanson JW, Holzer CE, Ganju VK, et al. Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area. surveys. Hosp Community Psychiatry 1990; 41: 761–70PubMedGoogle Scholar
  158. 158.
    Link BG, Andrews H, Cullen FT. The violent and illegal behavior of mental patients reconsidered. Am Sociol Rev 1992; 57: 275–92CrossRefGoogle Scholar
  159. 159.
    Guy E, Piatt JJ, Zwerling I, et al. Mental health status of prisoners in an urban jail. Crim Justice Behav 1985; 12: 29–53CrossRefGoogle Scholar
  160. 160.
    Fein R. Economics of mental illness. New York: Basic Books. 1958CrossRefGoogle Scholar
  161. 161.
    Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994; l65Suppl. 25: 18–21Google Scholar
  162. 162.
    Meltzer HY, Cola P, Way L. et al. Cost effectiveness of clozapine in antipsychotic-resistant schizophrenia. Am J Psychiatry 1993; 150(11): 1630–8PubMedGoogle Scholar
  163. 163.
    Meibach RC and the Risperidone Study Group. A fixed dose, parallel group study of risperidone vs haloperidol vs placebo [abstract]. Schizophr Res 1993; 9: 245CrossRefGoogle Scholar
  164. 164.
    Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–35PubMedGoogle Scholar
  165. 165.
    Mechanic D, Aiken LH. Improving the care of patients with chronic mental illness. N Engl J Med 1987; 317(26): 1635–8CrossRefGoogle Scholar
  166. 166.
    Terkelsen KG, McCarthy RH, Munich RL, et al. Development of clinical methods for utilization review in psychiatric day treatment. J Ment Health Admin 1994; 21(3): 298–312CrossRefGoogle Scholar
  167. 167.
    National Association of Psychiatric Hospital Systems. 1992 annual survey: final report. Washington, DC: National Association of Psychiatric Health Systems, 1993: 15Google Scholar
  168. 168.
    Rupp A, Keith SJ. The costs of schizophrenia: assessing the burden. Psychiatr Clin North Am 1993; 16(2): 413–23PubMedGoogle Scholar
  169. 169.
    Robinson JC. The changing boundaries of the American hospital. Milbank Q 1994; 72: 259–75PubMedCrossRefGoogle Scholar
  170. 170.
    Lewandowski L, Buchkremer G, Hermann T. The effectiveness of ambulatory occupational therapy measures for patients with schizophrenia [in German]. Psychiatr Prax 1992; 19(4): 122–8PubMedGoogle Scholar
  171. 171.
    Leff JP. Developments in family treatment of schizophrenia. Psychiatric Q 1979; 51: 216–32CrossRefGoogle Scholar
  172. 172.
    Cohen CI. Poverty and the course of schizophrenia: implications for research and policy. Hosp Community Psychiatry 1993; 44(1): 951–8PubMedGoogle Scholar
  173. 173.
    Asbaugh JW, Manderscheid RW. A method for estimating the chronic mentally ill population in stale and local areas. Hosp Community Psychiatry 1985; 36(4): 389–93Google Scholar
  174. 174.
    Black BJ. Substitute permanent employment of the deinslitulionalized mentally ill. J Rehabil 1977; 43(2): 32–9PubMedGoogle Scholar
  175. 175.
    Ozawa MN, Lindsey D. Is SSI too supportive of the mentally ill? Public Welfare 1977; 35 (4): 48–52Google Scholar
  176. 176.
    Lamb HR. Incentives and disincentives of disability insurance for the chronically mentally ill. In: Meyerson AT, Fine T, editors. Psychiatric rehabilitation: clinical, legal, and administrative dimensions. Washington, DC: American Psychiatric Press, 1987: 343–50Google Scholar
  177. 177.
    Berkowitz M. Disincentives and the rehabilitation of disabled persons. In: Pan EL, Backer TE, Vash CL, editors. Annual review of rehabilitation. Vol 2. New York: Springer Publishing, 1981Google Scholar
  178. 178.
    Black BJ. Work and mental illness: transitions to employment. Baltimore (MD): Johns Hopkins University Press, 1988Google Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Kenneth C. Terkelsen
    • 1
  • Alan Menikoff
    • 2
  1. 1.Department of Clinical PsychiatryThe New York Hospital, Cornell Medical Center, Cornell University Medical College, Westchester DivisionWhite PlainsUSA
  2. 2.Search for Change Inc. and US Behavioural Home Care Inc.WestportUSA

Personalised recommendations